Cell Therapy News

Lifileucel induced high response rates among patients with advanced melanoma whose disease progressed on immune checkpoint and BRAF/MEK inhibitors, according to study results presented during the ASCO20 Virtual Scientific Program.

The FDA granted fast track designation to TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme, according to the agent’s manufacturer.

Autologous hematopoietic stem cell transplant conferred survival outcomes comparable to chimeric antigen receptor T-cell therapy for certain patients with lymphoma, according to results presented during the ASCO20 Virtual Scientific Program.

The National Comprehensive Cancer Network and NCCN Foundation announced five recipients of the 10th annual NCCN Foundation Young Investigator Awards.

The FDA cleared an investigational new drug application for AgenT-797 for the treatment of patients with COVID-19 infection, according to the agent’s manufacturer.

An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.

Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory multiple myeloma, according to initial results of the phase 2 KarMMa trial presented during the ASCO20 Virtual Scientific Program.

JNJ-4528, a chimeric antigen receptor T-cell therapy, induced early, deep and durable responses among patients with relapsed or refractory multiple myeloma, according to study results presented during the ASCO20 Virtual Scientific Program.

Axicabtagene ciloleucel induced higher response rates than standard therapies among a subset of patients with lymphoma, according to study results presented at the virtual American Society of Gene and Cell Therapy Annual Meeting.